Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-07-18
1997-11-25
Rotman, Alan L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
5462794, A61K 3144, C07D40104
Patent
active
056913656
ABSTRACT:
Nicotine analogs that have nicotinic receptor antagonist properties. These compounds have been shown to competitively inhibit dopamine release induced by nicotine. The nicotine analog compounds are useful in the treatment of nicotine abuse, smoking cessation therapy, as an antidote for nicotine intoxication, treatment of cognitive disorders such as Alzheimer's disease and for the treatment of Parkinson's disease.
REFERENCES:
patent: 4965074 (1990-10-01), Leeson
patent: 5069904 (1991-12-01), Masterson
patent: 5187169 (1993-02-01), Lippiello et al.
patent: 5227391 (1993-07-01), Caldwell et al.
patent: 5232933 (1993-08-01), Lippiello et al.
patent: 5272155 (1993-12-01), Arneric et al.
patent: 5276043 (1994-01-01), Lippiello et al.
patent: 5278176 (1994-01-01), Lin
patent: 5298257 (1994-03-01), Bannon et al.
patent: 5316759 (1994-05-01), Rose et al.
patent: 5362496 (1994-11-01), Baker et al.
patent: 5369028 (1994-11-01), Harpold et al.
patent: 5371188 (1994-12-01), Heinemann et al.
Huang et al., Journal of the American Society for Mass Spectrometry, vol. 5 (No. 10), pp. 935-948, Elsevier Pub. Oct. 1994.
Chemical Abstracts, vol. 86 (No. 13) abst. No. 90, 110p, Mar. 28, 1977.
Chemical Abstracts, vol. 73 (No. 17) Abst. No. 87,738-a Oct. 26, 1970.
Janson, A.M. et al., "Chronic nicotine treatment decreases dopamine D2 agonist binding in the rat basal ganglia." Neuroreport, vol. 3, No. 12, pp. 1117-1120, 1992.
Boksa, P. et al., "Pharmacological activity of N-methyl-carbamylcholine, a novel acetylcholine receptor agonist with selectivity for nicotinic receptors." Eur. J. Pharmacol., vol. 173, No. 1, pp. 93-108, 1989.
Limberger, N. et al., "A search for receptors modulating the release of Neurochem., vol. 46, No. 4, pp. 1109-1117, 1986.
Corcoran, J.J. et al., "Inhibition of calcium uptake, sodium uptake, and catecholamine secretion by methoxyverapamil (D600) in primary cultures of adrenal medulla cells." J. Neurochem., vol. 40, No. 4, pp. 1106-1109, 1983.
Neubig, R.R. et al., "Permeability control by cholinergic receptors in Torpedo postsynaptic membranes: agonist dose-response relations measured at second and millisecond times." Biochemistry, vol. 19, No. 12, pp. 2770-2779, 1980.
Clarke, P.B., "Nicotine dependence--mechanisms and therapeutic strategies." Biochem. Soc. Symp., vol. 59, pp. 83-95, 1993.
Abood, L.G. et al., "Sites, mechanisms, and structural characteristics of the brain's nicotine receptor." J. Subst. Abuse, vol. 1, No. 3, pp. 259-271, 1989.
Calogero, A.E. et al., "Effect of cholinergic agonists and antagonists on rat hypothalamic corticotropin-releasing hormone secretion in vitro." Neuroendocrinology, vol. 47, No. 4, pp. 303-308, 1988.
Crooks Peter A.
Dwoskin Linda P.
Ravard Alain
Rotman Alan L.
University of Kentucky Research Foundation
LandOfFree
Nicotinic receptor antagonists in the treatment of neuropharmaco does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nicotinic receptor antagonists in the treatment of neuropharmaco, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nicotinic receptor antagonists in the treatment of neuropharmaco will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2107442